NO20056056L - N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer - Google Patents
N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorerInfo
- Publication number
- NO20056056L NO20056056L NO20056056A NO20056056A NO20056056L NO 20056056 L NO20056056 L NO 20056056L NO 20056056 A NO20056056 A NO 20056056A NO 20056056 A NO20056056 A NO 20056056A NO 20056056 L NO20056056 L NO 20056056L
- Authority
- NO
- Norway
- Prior art keywords
- peroxisome proliferator
- activated receptors
- actyl
- ligands
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47206703P | 2003-05-20 | 2003-05-20 | |
PCT/EP2004/005434 WO2004103995A1 (fr) | 2003-05-20 | 2004-05-19 | Heterocycles d'azote n-acyle utilises comme ligands des recepteurs actives par les proliferateurs de peroxysomes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20056056L true NO20056056L (no) | 2006-02-17 |
Family
ID=33476920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20056056A NO20056056L (no) | 2003-05-20 | 2005-12-20 | N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer |
Country Status (26)
Country | Link |
---|---|
US (1) | US7652061B2 (fr) |
EP (1) | EP1638963B1 (fr) |
JP (1) | JP4637843B2 (fr) |
KR (2) | KR100909918B1 (fr) |
CN (1) | CN1795193B (fr) |
AR (1) | AR044399A1 (fr) |
AT (1) | ATE442365T1 (fr) |
AU (1) | AU2004240754B9 (fr) |
BR (1) | BRPI0410779A (fr) |
CA (1) | CA2525764C (fr) |
CL (1) | CL2004001169A1 (fr) |
CO (1) | CO5650248A2 (fr) |
DE (1) | DE602004023080D1 (fr) |
EC (1) | ECSP056175A (fr) |
ES (1) | ES2331131T3 (fr) |
IS (1) | IS8160A (fr) |
MA (1) | MA27777A1 (fr) |
MX (1) | MXPA05012465A (fr) |
NO (1) | NO20056056L (fr) |
PE (1) | PE20050157A1 (fr) |
PT (1) | PT1638963E (fr) |
RU (1) | RU2374241C2 (fr) |
TN (1) | TNSN05295A1 (fr) |
TW (1) | TW200524918A (fr) |
WO (1) | WO2004103995A1 (fr) |
ZA (1) | ZA200508905B (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1822820A (zh) * | 2003-07-28 | 2006-08-23 | 雷迪实验室有限公司 | 心血管疾病的治疗和预防 |
EP1758580A4 (fr) | 2004-06-24 | 2008-01-16 | Incyte Corp | Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques |
US20060009471A1 (en) * | 2004-06-24 | 2006-01-12 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
PE20060594A1 (es) * | 2004-09-09 | 2006-08-18 | Novartis Ag | Composicion farmaceutica que contiene un agonista de ppar |
ATE539743T1 (de) * | 2005-06-27 | 2012-01-15 | Newtree Co Ltd | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan |
PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
ES2430115T3 (es) | 2006-03-31 | 2013-11-19 | Novartis Ag | Inhibidor de DGAT |
PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
KR20110028661A (ko) | 2008-07-15 | 2011-03-21 | 노파르티스 아게 | Dgat1 억제제로서의 헤테로아릴 유도체 |
JP5062097B2 (ja) * | 2008-08-21 | 2012-10-31 | 富士通株式会社 | 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム |
US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
AR083317A1 (es) | 2010-10-07 | 2013-02-13 | Novartis Ag | Forma cristalina de la sal sodica del acido (4-{4-[5-(6-trifluorometil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, composicion farmaceutica y un proceso para la elaboracion de la modificacion c |
AP3807A (en) | 2011-01-13 | 2016-09-30 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
CN103596569A (zh) | 2011-01-13 | 2014-02-19 | 诺瓦提斯公司 | 用于治疗代谢障碍的bace-2抑制剂 |
US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
BR112013026361A2 (pt) | 2011-04-14 | 2016-12-27 | Novartis Ag | derivados de glicosídeo e usos dos mesmos |
JP6047563B2 (ja) | 2011-07-08 | 2016-12-21 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の治療におけるその使用 |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
WO2013043744A2 (fr) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Composés tricycliques utiles comme agents neurogènes et neuroprotecteurs |
CN103987710A (zh) | 2011-10-13 | 2014-08-13 | 诺华股份有限公司 | 新的*嗪衍生物及它们在治疗疾病中的应用 |
MX2014006409A (es) | 2011-11-28 | 2014-07-30 | Novartis Ag | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG11201406526WA (en) | 2012-04-27 | 2014-11-27 | Novartis Ag | Cyclic bridgehead ether dgat1 inhibitors |
US9108956B2 (en) | 2012-04-27 | 2015-08-18 | Novartis Ag | Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors |
EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2943075C (fr) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Composes heterocycliques destines a etre utilises dans le traitement de troubles medies par pi3k-gamma |
US20170204149A1 (en) | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
EP3393494A1 (fr) | 2015-12-22 | 2018-10-31 | Novartis Ag | Méthodes de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur-15 de croissance et de différenciation (gdf-15) |
WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
EP3437651A1 (fr) | 2017-08-03 | 2019-02-06 | Université de Strasbourg | Peptides pour le traitement et la prévention de la stéatose hépatique non alcoolique |
US11530241B2 (en) | 2017-12-14 | 2022-12-20 | Universite De Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis |
CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽 |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
EP3887363A1 (fr) | 2018-11-27 | 2021-10-06 | Novartis AG | Composés pentamères cycliques servant d'inhibiteurs de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) pour le traitement d'un trouble métabolique |
ES2948264T3 (es) | 2018-12-21 | 2023-09-07 | Univ Strasbourg | Péptidos para el tratamiento y prevención de la diabetes y trastornos asociados |
WO2022219495A1 (fr) | 2021-04-12 | 2022-10-20 | Novartis Ag | Dérivés de 2-((4-((s)-2-(4-chloro-2-fluorophényl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-imidazole utilisés en tant qu'activateurs du récepteur glp1 pour le traitement de l'obésité |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
TW202342014A (zh) | 2022-02-10 | 2023-11-01 | 瑞士商諾華公司 | 1,3-苯并二氧戊環衍生物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5045540A (en) * | 1990-05-25 | 1991-09-03 | Warner-Lambert Co. | Amino acid derivatives with angiotensin II antagonist properties |
ES2182203T3 (es) * | 1997-10-31 | 2003-03-01 | Hoffmann La Roche | Derivados de d-prolina. |
AU4180900A (en) * | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2004
- 2004-05-19 AT AT04739269T patent/ATE442365T1/de active
- 2004-05-19 JP JP2006529884A patent/JP4637843B2/ja not_active Expired - Fee Related
- 2004-05-19 AU AU2004240754A patent/AU2004240754B9/en not_active Ceased
- 2004-05-19 CN CN2004800140213A patent/CN1795193B/zh not_active Expired - Fee Related
- 2004-05-19 US US10/556,988 patent/US7652061B2/en not_active Expired - Fee Related
- 2004-05-19 PE PE2004000511A patent/PE20050157A1/es not_active Application Discontinuation
- 2004-05-19 TW TW093114121A patent/TW200524918A/zh unknown
- 2004-05-19 BR BRPI0410779-9A patent/BRPI0410779A/pt not_active IP Right Cessation
- 2004-05-19 PT PT04739269T patent/PT1638963E/pt unknown
- 2004-05-19 KR KR1020087000342A patent/KR100909918B1/ko not_active IP Right Cessation
- 2004-05-19 RU RU2005139525/04A patent/RU2374241C2/ru not_active IP Right Cessation
- 2004-05-19 AR ARP040101732A patent/AR044399A1/es not_active Application Discontinuation
- 2004-05-19 WO PCT/EP2004/005434 patent/WO2004103995A1/fr active Application Filing
- 2004-05-19 ES ES04739269T patent/ES2331131T3/es not_active Expired - Lifetime
- 2004-05-19 CA CA2525764A patent/CA2525764C/fr not_active Expired - Fee Related
- 2004-05-19 KR KR1020057022001A patent/KR100849747B1/ko not_active IP Right Cessation
- 2004-05-19 DE DE602004023080T patent/DE602004023080D1/de not_active Expired - Lifetime
- 2004-05-19 MX MXPA05012465A patent/MXPA05012465A/es active IP Right Grant
- 2004-05-19 EP EP04739269A patent/EP1638963B1/fr not_active Expired - Lifetime
- 2004-05-20 CL CL200401169A patent/CL2004001169A1/es unknown
-
2005
- 2005-11-03 ZA ZA200508905A patent/ZA200508905B/xx unknown
- 2005-11-15 MA MA28605A patent/MA27777A1/fr unknown
- 2005-11-18 TN TNP2005000295A patent/TNSN05295A1/en unknown
- 2005-11-18 EC EC2005006175A patent/ECSP056175A/es unknown
- 2005-11-30 IS IS8160A patent/IS8160A/is unknown
- 2005-12-15 CO CO05126527A patent/CO5650248A2/es not_active Application Discontinuation
- 2005-12-20 NO NO20056056A patent/NO20056056L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20056056L (no) | N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer | |
ECSP045103A (es) | Compuestos heterociclicos y metodos de uso | |
BRPI0412380A (pt) | compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos | |
MX2009003222A (es) | Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. | |
ATE386715T1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
MXPA06003055A (es) | Compuestos organicos. | |
Laufer et al. | Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes | |
WO2010036613A8 (fr) | Nouveaux dérivés de benzimidazole cycliques utiles en tant qu'agents anti-diabétiques | |
PH12016502294A1 (en) | Novel fatty acids and their use in conjugation to biomolecules | |
WO2006067224A3 (fr) | Nouveaux composes | |
RU2010120808A (ru) | Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение | |
BRPI0407180A (pt) | Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto | |
NZ715983A (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
JP2006527210A (ja) | ホルモン感受性リパーゼ阻害剤としてのピリジニルカルバメート | |
CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
EA200601869A1 (ru) | Карбоновые кислоты | |
WO2005115383A3 (fr) | Triazoles substitués comme modulateurs de ppar et méthodes de préparation | |
WO2004037248A3 (fr) | Modulation de l'activite des recepteurs actives par les proliferateurs de peroxysomes | |
MY148434A (en) | Fused bicyclic heteroaryl derivatives | |
Arhancet et al. | Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines | |
RU2012113924A (ru) | 5-(3,4-дихлорфенил)-n-(2-гидроксициклогексил)-6-(2,2,2-трифторэтокси)никотинамид и его соли в качестве средств, повышающих концентрацию лвп холестерина | |
DE602005024384D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
BR0318685A (pt) | compostos de cetona e composições para controle de colesterol e usos relacionados | |
CA2526518A1 (fr) | Derives de 1-aryl-4-(aryloxycarbonyl)-piperazine utilises en tant qu'inhibiteurs de la lipase hormonosensible |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |